"Drug Synergism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
| Descriptor ID |
D004357
|
| MeSH Number(s) |
G07.690.773.968.477
|
| Concept/Terms |
Drug Synergism- Drug Synergism
- Drug Synergisms
- Synergism, Drug
- Synergisms, Drug
Drug Potentiation- Drug Potentiation
- Drug Potentiations
- Potentiation, Drug
- Potentiations, Drug
Drug Augmentation- Drug Augmentation
- Augmentation, Drug
- Augmentations, Drug
- Drug Augmentations
|
Below are MeSH descriptors whose meaning is more general than "Drug Synergism".
Below are MeSH descriptors whose meaning is more specific than "Drug Synergism".
This graph shows the total number of publications written about "Drug Synergism" by people in this website by year, and whether "Drug Synergism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 6 | 6 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 9 | 9 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 8 | 8 |
| 2009 | 0 | 8 | 8 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 7 | 7 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 5 | 5 |
| 2016 | 0 | 9 | 9 |
| 2017 | 0 | 7 | 7 |
| 2018 | 1 | 5 | 6 |
| 2019 | 1 | 8 | 9 |
| 2020 | 0 | 9 | 9 |
| 2021 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. Int J Mol Sci. 2024 Aug 26; 25(17).
-
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer. J Exp Clin Cancer Res. 2024 Aug 21; 43(1):236.
-
Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Med. 2024 Aug; 13(15):e70031.
-
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary. Mol Ther. 2024 Oct 02; 32(10):3650-3668.
-
Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy. Oncotarget. 2024 Jun 03; 15:361-373.
-
IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy. Clin Cancer Res. 2024 Jun 03; 30(11):2558-2570.
-
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts. Sci Rep. 2022 07 29; 12(1):12984.
-
Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer. Pharm Res. 2022 Mar; 39(3):511-528.
-
Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Leuk Lymphoma. 2022 07; 63(7):1634-1644.
-
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022 02 10; 139(6):907-921.